Key result
Percutaneous LAAC matches oral anticoagulants for stroke prevention while cutting major bleeding ~72% after 6 months.
Why the study?
Anticoagulant therapy is widely recommended for embolic stroke prevention in non-valvular atrial fibrillation but bleeding risk remains a concern, prompting evaluation of percutaneous left atrial appendage closure as a novel, less invasive treatment.
Does percutaneous left atrial appendage closure prevent embolic stroke and reduce bleeding risk compared to oral anticoagulation in patients with non-valvular atrial fibrillation?
Does percutaneous left atrial appendage closure prevent embolic stroke and reduce bleeding risk compared to oral anticoagulation in patients with non-valvular atrial fibrillation?
Percutaneous left atrial appendage closure is an evolving, minimally invasive alternative to oral anticoagulants for stroke prevention in non-valvular atrial fibrillation, with expanding indications, simplified post-operative antithrombotic strategies, and potential for simultaneous application with catheter ablation.
May support LAA closure to reduce bleeding in select NVAF patients; leaves open confirmation of long-term stroke prevention in randomized trials.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Ryuzaki et al. (2025) conducted a review in Non-valvular atrial fibrillation. Percutaneous left atrial appendage closure (LAAC) vs. Oral anticoagulation (Warfarin or DOAC) was evaluated. Percutaneous left atrial appendage closure provides comparable stroke prevention to oral anticoagulants in non-valvular atrial fibrillation, demonstrating a 72% reduction in major bleeding after 6 months in a pooled trial analysis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: